🔥

Retatrutide

LY3437943 · Triple G agonist

Moderate Evidence📈 TrendingFat Loss & Metabolic

A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.

Half-Life

~6 days

Large peptide ~5200 Da

Amino Acids

N/A

Evidence

Moderate Evidence

Add to Protocol

Regulatory Status

Investigational. Phase III clinical trials. Not yet approved.

How it works: Add BAC water to your vial → calculator finds concentration → divides your dose by concentration → shows units to draw on a standard 100-unit insulin syringe. Values are pre-filled from research reference defaults — adjust to match your actual vial.

Vial Size (mg)

BAC Water (mL)

Dose (mcg)

fill level

Draw

—

units on a 100-unit syringe

Conc.

—

mcg/mL

Vol/dose

—

Doses/vial

—

inj.

Titration Schedule

Weeks 1–42 mgStart here

Weeks 5–84 mg

Weeks 9–168 mg

Weeks 17+12 mg

Research reference values only. Confirm all parameters with current literature and your clinician.

Looking for multi-compound protocols?

Browse educational protocol discussions that include Retatrutide.

Protocol Library

Related Compounds

Tirzepatide

A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.

Semaglutide

A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.

Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.